Recently, Longyao Biotech, together with its R&D partner ViroMissile, announced that its strategically upgraded product IDOV-Immune™ has been granted FDA IND approval and will soon initiate a Phase I clinical trial in the United States. Developed on t
2026.02.18
On May 30, 2025, Longyao Bio and ViroMissile announced IDOV‑Immune™ received ethics approval from The Alfred Hospital Melbourne, Australia, launching its Phase I trial, a key step in global development.
2026.01.09
On May 15, 2025, Dr. Chen Nanhai, Chief Scientist of Longyao Bio, was featured in Life Sciences Review and awarded “Top Cancer Destroying Platform 2025”. Its IDOV™ platform pioneers intravenous oncolytic vaccinia virus, advancing “one-shot cure” for solid
2026.01.09
On March 24, 2025, Longyao Bio's IDOV-Safe™ received ethical approval from Beijing Gobroad Hospital, expanding its multi-center clinical footprint in northern China.
2026.01.09
On July 29, 2024, Longyao Bio’s IDOV‑Safe™ obtained ethical approval from Fudan University Shanghai Cancer Center. Led by PI Professor Wang Hongxia, the trial officially starts, marking a key step in its national multi-center clinical development.
2025.05.30
On February 21, 2024, Longyao Biotech's IDOV-Safe™ received ethical approval from Cancer Hospital, CAMS, with President Li Ning as PI. As China’s top oncology center, this approval represents a major milestone.
2024.02.21
On January 26, 2024, Longyao Biotech’s core product IDOV-Safe™ was granted ethical approval by Peking University Cancer Hospital. The clinical trial was officially initiated, led by Professor Shen Lin, Director of the Department of Gastroenterology as the
2024.01.31
Address
Room 2101, Xingtong Building, No. 88 Baoxing Road, Haiwang Community, Xin'an Sub-district, Bao'an District, Shenzhen City.
Postal Code:518101
Tel
0755-23000529
Email
info@longyaobio.com
